-去背.png){kind=logo}
Taipei, Taiwan — 9 October 2026
TFBS Bioscience, Inc. (TPEX: 6939; Headquarters: New Taipei City, Taiwan; hereinafter "TFBS") and TOKIWA Bio Inc. (Headquarters: Tsukuba City, Ibaraki Prefecture, Japan; hereinafter "TOKIWA Bio") held a joint signing ceremony at "BioJapan 2026" in Pacifico Yokohama to mark their strategic business partnership in the fields of cell therapy and regenerative medicine.
Representatives from both companies took the stage to sign the agreement and jointly announced the establishment of a partnership for future business expansion.
[Purpose of the Partnership and Future Outlook]
Through this partnership, the two companies aim to offer solutions leveraging their respective strengths by integrating TOKIWA Bio's proprietary "Stealth RNA Vector (SRV®)" technology with TFBS's global-standard analytical and quality control expertise and virus vector CDMO (Contract Development and Manufacturing Organization) capabilities. Moving forward, by fusing their key advantages to build a comprehensive support framework ranging from process development and GMP manufacturing to quality and safety evaluation, both companies will jointly promote the creation of new markets and maximize synergies in the gene and cell therapy sectors across Japan, Taiwan, and globally.
Signing Ceremony Photo: Dr. Masato Nakanishi, Representative Director and CEO of TOKIWA Bio Co., Ltd. (front row, left), and Dr. Tatung Yuan, Chairman and CEO of TFBS Bioscience, Inc. (front row, right).
[Executive Quotes]
Tatung Yuan, Ph.D., Chairman & CEO, TFBS Bioscience, Inc.
"We are delighted to enter into this strategic partnership with TOKIWA Bio. By integrating their innovative Stealth RNA Vector (SRV®) technology with TFBS’s established global-standard viral vector CDMO capabilities and rigorous quality and safety evaluation expertise, we can deliver higher-quality, more efficient one-stop solutions for the cell and gene therapy sector. Through this collaboration, we aim to maximize our synergies and together accelerate the delivery of innovative regenerative medicine therapies to patients in Japan, Taiwan, and around the world."
Mahito Nakanishi, Ph.D., Representative Director & CEO, TOKIWA Bio Inc.
"The latest vector for iPS cell production developed by our company (development code: SRV374(EZ711)) represents world-class iPS cell production technology capable of rapidly generating high-quality human iPS cells with exceptional efficiency. Sales as a research reagent are scheduled to begin in Japan in December 2026, while we continue preparations to launch clinical-grade products. We are extremely pleased to partner with TFBS as the first step in this journey. TFBS is an academia-launched venture founded around the same time as our company, and under Dr. Yuan’s strong leadership, it has accumulated a solid track record in virus vector manufacturing. As partners dedicated to pioneering a new era of healthcare through biotechnology, we look forward to deepening our international collaboration with TFBS."
■About TFBS Bioscience, Inc.
TFBS Bioscience Inc. (TFBS) was founded in 2016 as the first contract research organization providing biological testing in Taiwan after its spin-off from Development Center for Biotechnology, a government-sponsored research institute. TFBS has established strong track records in several regulatory submissions, winning trust from the international regulatory agencies and biopharmaceutical industry. TFBS has launched the first viral vector contract development and manufacturing facility in Taiwan, providing fully integrated end-to-end contract development and manufacturing services for the needs of clinical trials. TFBS offers manufacturing expertise in adeno-associated virus, lentivirus, and retrovirus. With the customization specialty and state-of-the-art facility, TFBS is the best partner offering clients a one-stop-shop solution for gene and cell therapy. For more information, please visit https://www.tfbsbio.com.
■About TOKIWA Bio Inc.
TOKIWA Bio Inc. is a bioventure founded in 2014 based on research outcomes from the National Institute of Advanced Industrial Science and Technology (AIST). Utilizing 100% Japanese-developed Stealth RNA Vector (SRV®) technology, the company develops foundational technologies supporting gene/cell therapy and regenerative medicine. Its breakthroughs are expected to see broad applications across diverse fields, including the generation of high-safety clinical-grade iPS cells, various cell reprogramming processes, drug discovery research, and biopharmaceutical manufacturing. Through innovative RNA vector technology originating in Japan, TOKIWA Bio aims to contribute to patients suffering from intractable diseases worldwide. For more information, please visit https://tokiwa-bio.com.
[Media Contact]
TFBS Bioscience, Inc.
Yutaka Mitsuo, Business Development Director
service@tfbsbio.com
TOKIWA Bio Inc.
Public Relations
press-tokiwa@tokiwa-bio.com